INTANGIBLE ASSETS (Details Narrative) - USD ($)
|
1 Months Ended |
3 Months Ended |
6 Months Ended |
12 Months Ended |
Apr. 30, 2022 |
Sep. 30, 2021 |
Jan. 31, 2021 |
Dec. 31, 2020 |
Oct. 31, 2020 |
Mar. 31, 2020 |
Dec. 31, 2021 |
Mar. 31, 2021 |
Jun. 30, 2020 |
Mar. 31, 2020 |
Jun. 30, 2022 |
Jun. 30, 2021 |
Dec. 31, 2021 |
Dec. 31, 2020 |
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued to acquire license |
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,425,000
|
$ 106,000
|
| Common stock issued for services, value |
|
|
|
|
|
|
$ 21,960
|
|
$ 23,300
|
$ 15,000
|
$ 51,750
|
$ 430,427
|
540,136
|
36,800
|
| Common stock issued for services, shares |
|
|
|
|
|
|
200,000
|
6,500,000
|
1,250,000
|
1,500,000
|
|
|
|
|
| Payment for royalty free perpetual license |
|
|
|
|
|
|
|
|
|
|
40,632
|
$ 8,500
|
14,500
|
$ 34,300
|
| Website [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued for services, value |
|
|
|
$ 22,500
|
|
$ 15,000
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets, Remaining Amortization Period |
|
|
|
3 years
|
|
|
|
|
|
|
|
|
|
|
| Amortization of Intangible Assets |
|
|
|
|
|
|
|
|
|
|
$ 3,750
|
|
$ 6,250
|
|
| Common stock issued for services, shares |
|
|
|
|
|
1,500,000
|
|
|
|
|
|
|
|
|
| Patents [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| License transaction description |
|
|
|
|
The
total cost for this license is 20 million shares of the Company’s common stock, issuable in three tranches - 1- 7 million shares
upon execution of the license (which have been issued, valued at $91,000), 2- 6.5 million shares upon the submission of an Investigational
New Drug (IND) to the FDA and 3- 6.5 million shares upon the successful completion of the first rabies clinical trial of this IND. This
license calls for royalties of 50% of the net profit, after reimbursement for development costs, of successfully marketed products utilizing
IMT504.
|
|
|
|
|
|
|
|
|
|
| Patents [Member] | Investigational New Drug [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued to acquire license, shares |
|
|
|
|
20,000,000
|
|
|
|
|
|
|
|
|
|
| Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued to acquire license, shares |
|
|
|
|
7,000,000
|
|
|
|
|
|
|
|
|
|
| Common stock issued to acquire license |
|
|
|
|
$ 91,000
|
|
|
|
|
|
|
|
|
|
| Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche One [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued to acquire license, shares |
|
|
|
|
1,000,000
|
|
|
|
|
|
|
|
|
|
| Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche One [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued to acquire license, shares |
|
|
|
|
7,000,000
|
|
|
|
|
|
|
|
|
|
| Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche Two [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued to acquire license, shares |
|
|
|
|
6,500,000
|
|
|
|
|
|
|
|
|
|
| Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued to acquire license, shares |
|
|
|
|
2,000,000
|
|
|
|
|
|
|
|
|
|
| Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued to acquire license, shares |
|
|
|
|
6,500,000
|
|
|
|
|
|
|
|
|
|
| Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche Three [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued to acquire license, shares |
|
|
|
|
6,500,000
|
|
|
|
|
|
|
|
|
|
| Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche Three [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued to acquire license, shares |
|
|
|
|
3,000,000
|
|
|
|
|
|
|
|
|
|
| Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche Three [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued to acquire license, shares |
|
|
|
|
6,500,000
|
|
|
|
|
|
|
|
|
|
| National Institute of Health Patent License One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payment of non-refundable license issue royalty |
|
|
|
|
$ 10,000
|
|
|
|
|
|
|
|
|
|
| National Institute of Health Patent License Two [Member] | Royalty [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Patent expense initial amount payable |
|
|
$ 8,500
|
|
|
|
|
|
|
|
|
|
|
|
| National Institute of Health Patent License Two [Member] | Royalty One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Option extension description |
|
|
The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time
non-refundable non-creditable royalty of $45,000. There are three benchmark royalties - $75,000 upon the initiation of the first Phase
2 Clinical Study; $300,000 upon the completion of Phase 3 Clinical Study and $600,000 upon the FDA approval of the first Licensed Product.
Upon first commercial sale there is a royalty of $100,000 each for the United States, Canada, European Union and Asian region. Last is
a 3.5% of net sales royalty.
|
|
|
|
|
|
|
|
The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time non-refundable, non-creditable royalty of $45,000. There are three benchmark royalties - $75,000 upon the initiation of the first Phase 2 Clinical Study; $300,000 upon the completion of Phase 3 Clinical Study and $600,000 upon the FDA approval of the first Licensed Product. Upon first commercial sale there is a royalty of $100,000 each for the United States, Canada, European Union and Asian region. Last is a 3.5% of net sales royalty.
|
|
|
|
| Payment of non-refundable license issue royalty |
|
|
$ 45,000
|
|
|
|
|
|
|
|
|
|
|
|
| Patent expense initial amount payable |
|
|
$ 5,000
|
|
|
|
|
|
|
|
|
|
|
|
| Mid-Atlantic BioTheraputics, Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued to acquire license, shares |
|
|
|
|
|
|
12,500,000
|
|
|
|
|
|
|
|
| Common stock issued to acquire license |
|
|
|
|
|
|
$ 1,425,000
|
|
|
|
|
|
|
|
| Mid-Atlantic BioTheraputics, Inc [Member] | Patents [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds for patent license development |
|
|
|
|
6,500,000
|
|
|
|
|
|
|
|
|
|
| IEM, Inc [Member] | Patents [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cost of option |
|
|
|
|
$ 1,800
|
|
|
|
|
|
|
|
|
|
| Option extension description |
|
The
Company had until September 30, 2021, to advise IEM in writing that it wishes to exercise this Option Right and pay IEM $50,000 in exchange
for an exclusive world-wide, royalty free perpetual license. In September 2021, the Company exercised the option to extend the deadline
for notification in the contract with IEM, from September 30, 2020 to March 31, 2022, in exchange for the payment of $1,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payment for royalty free perpetual license |
|
$ 50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payment for extension |
$ 1,000
|
$ 1,000
|
|
|
|
|
|
|
|
|
|
|
|
|